Department of Internal Medicine, Mount Sinai School of Medicine, New York, NY, USA.
Pancreas. 2013 Mar;42(2):249-53. doi: 10.1097/MPA.0b013e31825f3af4.
Studies demonstrate safety and survival benefits of surgical resection in older individuals with pancreatic adenocarcinoma. We investigated treatment disparities by age.
The Surveillance, Epidemiology, and End Results database for survival and treatment of pancreatic adenocarcinoma between 1983 and 2007 stratified by age: younger than 50 years, between 50 and 70 years, or older than 70 years. Kaplan-Meier curves and Cox proportional hazards models were used for survival differences, and logistic regression models were used for treatment disparities and the decision to refuse surgery.
A total of 45,509 patients had microscopically confirmed pancreatic adenocarcinoma. Of these, 7374 (16%) received surgery and 9842 (22%) received radiation. Younger patients were more likely to receive both surgery and radiation. The prevalence of surgery decreased from 21% for those younger than 50 years to 19% for those between 50 and 70 years to 13% for those older than 70 years (P < 0.001). Radiation decreased from 28% to 25% to 17% (P < 0.001). Overall survival decreased with increasing age at diagnosis, 10.4 months (age <50 years) to 9.1 months (age 50-70 years) to 6.4 months (age >70 years) controlling for stage, sex, race, radiation, and surgery (P < 0.001). Increasing age negatively predicted the odds of receiving both surgery and radiation and increased the likelihood of refusing surgery.
Treatment disparities exist by age despite advances in radiation and surgical treatment. Increased treatment in the elderly will increase overall survival from pancreatic adenocarcinoma.
研究表明,对于患有胰腺腺癌的老年患者,手术切除具有安全性和生存获益。我们研究了按年龄划分的治疗差异。
使用监测、流行病学和最终结果数据库,对 1983 年至 2007 年间年龄分层(小于 50 岁、50-70 岁和大于 70 岁)的胰腺腺癌的生存和治疗情况进行分析。使用 Kaplan-Meier 曲线和 Cox 比例风险模型来比较生存差异,使用 logistic 回归模型来比较治疗差异和拒绝手术的决定。
共有 45509 例显微镜下确诊为胰腺腺癌的患者。其中,7374 例(16%)接受了手术,9842 例(22%)接受了放疗。年轻患者更有可能同时接受手术和放疗。手术的比例从 50 岁以下患者的 21%下降到 50-70 岁患者的 19%,再到 70 岁以上患者的 13%(P < 0.001)。放疗的比例从 28%下降到 25%,再到 17%(P < 0.001)。在控制分期、性别、种族、放疗和手术等因素后,总生存时间随着诊断时年龄的增加而下降,50 岁以下患者为 10.4 个月,50-70 岁患者为 9.1 个月,70 岁以上患者为 6.4 个月(P < 0.001)。随着年龄的增长,接受手术和放疗的可能性降低,拒绝手术的可能性增加。
尽管放疗和手术治疗取得了进展,但仍存在按年龄划分的治疗差异。对老年人进行更多的治疗将提高胰腺腺癌的总体生存率。